View abstract

Cet abstract a été assigné à sessions

Type de présentation	E-poster
Titre	Photographical overview of successful treatment of a basocellular carcinoma with vismodegib, a selective Hedgehog pathway inhibitor

But	We present a photographical overview of successful treatment of a basocellular carcinoma (BCC) of the left lower eyelid with Erivedge® (vismodegib).
Méthodes	One patient with a BCC of the left lower eyelid was treated with Erivedge® during 8 months.
Résultats	A 54-year-old woman presented with an extensive basal cell carcinoma of the left lower eyelid with infiltration into the inferior orbit. The diagnosis of a BCC was confirmed on biopsy. MRI of the orbit shows deep extension of the lesion into the orbit with enhancement of contrast including the insertion of the inferior oblique muscle and the inferior rectus muscle. Given the location and extent of the lesion, radical surgery and radiotherapy are not the first choice. Erivedge® is the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration approval in 2012. Erivedge is reimbursed in Belgium if demonstrated that it is administered for the treatment of adult patients with locally advanced basal cell carcinoma for whom surgery or radiotherapy is not a suitable treatment option, or for the treatment of adult patients with symptomatic metastatic basal cell carcinoma. This patient took one 150mg capsule of Erivedge every other day for 8 months but discontinued it due to persistent diarrhea.
Conclusion	This case discusses the effect of Erivedge in a 54-year-old woman with basal cell carcinoma located at the left lower eyelid. Erivedge is a viable alternative when radical surgery or radiotherapy are not suitable options.
Conflit d'intérêt	Non

Auteurs 1

Nom	COOLS
Initiales	A
Institut	Dpt of Ophthalmology, Ghent University Hospital
Ville	Ghent, Belgium

Auteurs 2

Nom	Ninclaus
Initiales	VGS
Institut	Dpt of Ophthalmology, Ghent University Hospital
Ville	Ghent, Belgium